ACCREDITATION STATEMENT
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Endocrine Society has achieved Accreditation with Commendation.

The Endocrine Society designates this activity for a maximum of 31 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

STATEMENT OF INDEPENDENCE
As a provider of continuing medical education (CME) accredited by the Accreditation Council for Continuing Medical Education, The Endocrine Society has a policy ensuring that the content and the quality of this educational program are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of The Endocrine Society's Clinical Endocrinology Update (CEU) Steering Committee. The commercial supporters of this activity have no influence over the selection of the faculty or specific presentations.

DISCLAIMER
The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of The Endocrine Society.

LEARNING OBJECTIVES
Upon completion of this educational activity, learners will be able to:

• Discuss state-of-the-art research in endocrinology
• Demonstrate updated knowledge of the diagnosis and treatment of diabetes, lipid, osteoporosis, pituitary, adrenal, thyroid, and reproductive endocrine disorders
• Employ enhanced skills and practice management techniques to improve patient care

TARGET AUDIENCE
This continuing medical education activity should be of substantial interest to endocrinologists, endocrine fellows, internists, healthcare professionals who treat endocrine disorders, and others seeking an update in recent developments in the treatment of endocrine disorders.

DISCLOSURE POLICY
The faculty, committee members, and staff involved in planning this CME activity are required to disclose to learners any relevant financial relationship(s) that have occurred within the last 12 months with any commercial interest(s) whose products or services are discussed in the CME content. Such relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent faculty with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments. It remains for learners to determine whether financial interests or relationships may influence the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following committee members who planned and/or reviewed content for this activity reported relevant financial relationships:

• John S. Adams, MD, has received research grant support from Quest and served as a consultant for Quest and Amgen.
• Richard J. Auchus, MD, PhD, has received honoraria serving as consultant for Bristol-Myers Squibb and Johnson & Johnson; has received research grant support from Novartis and Corcept Therapeutics.
• Glenn D. Braunstein, MD, has served as a consultant for Abbott Diagnostics and Esoterix.
• Kenneth Cusi, MD, has received speakers bureau honoraria from Abbott, AstraZeneca and Merck; has received research grant support from Amylin, Eli Lilly and Takeda.
• Robert F. Gagel, MD, has served as consultant for AstraZeneca, Eisai Pharmaceuticals, Amgen and Exelixis; received research grant support from AstraZeneca; served as a speaker for Exelixis.
• Irl B. Hirsch, MD, has received research grant support from Novo Nordisk and MannKind; has received consultant fees from Bayer, Roche, Johnson & Johnson and Abbott.
• Lois Jovanovic, MD, has received grant/research support from Amylin, Bristol MyersSquibb,Merck, Novo Nordisk, Pfizer, sanofi-aventis, and Sensys; has received honoraria for serving on advisory boards for Amylin, DexCom, Eli Lilly & Company, Insulet, LifeScan, Medtronics MiniMed, MannKind, Novo Nordisk, Pfizer, and Sensys.
• Laurence Katznelson, MD, has received research funding from Corcept.
• Jennifer L. Larsen, MD, has received research grant support from Eli Lilly.
• Susan J. Mandel, MD, MPH, has received research grant support from Novacyte.
• Paul D. Miller, MD, has received research grants from the Alliance for Better Bone Health (Procter & Gamble and sanofi-aventis), Roche-GSK, Lilly, Merck, Novartis and Amgen; has served on scientific advisory, or speakers, boards, or as a consultant, for the Alliance for Better Bone Health (Procter & Gamble and sanofi-aventis), Amgen, Lilly, Novartis, and Roche-GSK, Merck, and NPS.
• Dolores M. Shoback, MD, has served as consultant for Amgen and speaker for Novartis.
• Frederick R. Singer, MD, has received speaker honoraria from Novartis.
• Ronald S. Swerdloff, MD, has received research grant support from Clarus, EndoPharm and Solvay; has served as consultant for Clarus and EndoPharm.
• R. Michael Tuttle, MD, has received consultant fees from Abbott, Genzyme, Lilly and Novo Nordisk.
• Guillermo E. Umpierrez, MD, has received research grant support from sanofi-aventis, Takeda, and Baxter.
• Joseph G. Verbalis, MD, has received consultant fees from Astellas, Cardiokine, Otsuka, and sanofi-aventis.

The following faculty reported NO relevant financial relationships: Baha M. Arafah, MD; Paul M. Copeland, MD; Anita P. Courcoulas, MD; Daniel A. Dumesic, MD; Wylie C. Hembree, MD; Robert Levine, MD; Deborah Sellmeyer, MD; Leonard Wartofsky, MD; William F. Young, Jr., MD, MSc.

The following CEU Steering Committee members who planned and/or reviewed content for this activity reported relevant financial relationships:

• Steven T. Harris, MD, has served as speaker for Amgen, Eli Lilly & Company, Genentech, Gilead Sciences, GlaxoSmithKline, Novartis, Procter & Gamble, Roche, sanofi-aventis, and Wyeth; has served as consultant for Amgen, Eli Lilly & Company, Gilead Sciences, GlaxoSmithKline, Merck & Company, Novartis, Procter & Gamble, Roche, sanofi-aventis and Wyeth.
• Steven Hodak, MD, has served on speakers bureau for Novartis.
• Kathryn M. Martin, MD, is employed by UpToDate.
• Steven B. Nagelberg, MD, has served on speakers bureaus for sanofi-aventis, Lilly, Merck and Novo Nordisk.

The following CEU Steering Committee members who planned and/or reviewed content for this activity reported NO relevant financial relationships: Susan E. Kirk, MD; Mark E. Molitch.

The Endocrine Society staff associated with the development of the content for this activity reported no relevant financial relationships.

CONFLICT OF INTEREST STATEMENT
The scientific content of this activity was developed by The Endocrine Society's CEU Steering Committee, independent of grant support and in accordance with the ACCME's Essential Areas and Elements, including the Standards for Commercial Support. The commercial supporters of this meeting have no influence over topics or speakers.

POLICY ON UNLABELED/OFF-LABEL USAGE
The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation.

Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such "off-label" use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

PRIVACY & CONFIDENTIALITY STATEMENT
The Endocrine Society will record learner's personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.

ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
This activity is supported by educational grants from Amgen, Amylin Pharmaceuticals, Inc, Lilly USA, LLC, Geico, sanofi-aventis U.S., and Merck.

METHOD OF PARTICIPATION
This enduring material is presented in an online/computer-based format. System requirements include:

• For Windows, Firefox 1.5 or Internet Explorer 6.0 with Flash 8 or better installed.
• For Macintosh OS X, Safari 2.0 or Firefox 1.5 with Flash 8 or better installed.

The estimated time to complete this activity, including review of material, is 31 hours.

To receive a maximum of 31 AMA PRA Category 1 Credit(s)™ participants should:

• Select a session and listen to the audio and/or view the slides.
• Complete the evaluation provided at the end of the session and click on "submit" to add the session to the learner's transcript. The transcript will appear and the learner will have the option of printing a CME certificate then or at a later time, after viewing multiple sessions.
• Select additional sessions and proceed as directed above, to accumulate credits for participating in multiple sessions.
• Credits awarded correspond to the length of time for each session, which varies from 0.5 to 1.0 hours

Last Review Date: October 2010
Activity Release Date: October, 2010
Activity Expiration Date: October, 2011

For technical assistance or information, please contact call 972-910-6899 (9:00 AM to 5:00 PM EST) or E-mail: multiviewMediaSupport@multiview.com.

For questions regarding CME content or obtaining CME credit, please contact The Endocrine Society at 301.941.0200 or education@endo-society.org.

I have read the CME guidelines outlined.